NPY favors breast tumor cell proliferation/migration and angiogenesis [93,94], whereas Y5R antagonists (e.g., CGP71683A) not only decreased the cell growth/migration of these cells but also promoted the death of breast cancer cells [97]. Here, NPY is linked to breast carcinoma.